On December 23, 2025, the U.S. Food and Drug Administration granted approval for Novo Nordisk’s oral formulation of Wegovy, marking the first FDA-approved pill in its obesity treatment franchise. Clinical data presented to regulators showed an average weight loss of 16.6% for patients receiving the oral treatment over 64 weeks, compared with 12.4% observed in Lilly’s orforglipron study at 72 weeks. The approval positions Novo Nordisk to begin commercial launch in January 2026, outpacing the anticipated entry of competing oral therapies by at least two months.

Novo Nordisk’s third-quarter sales growth slowed dramatically to 5%, down from 21% in the prior year period. This deceleration coincided with the market entry of Lilly’s injectable tirzepatide in November 2023, which captured a larger share of the incretin analog segment. While Novo’s global obesity care revenues exceeded $8.5 billion for the first nine months of 2025, Lilly’s weight loss franchise achieved 54% growth in the same quarter, underscoring intensifying competitive dynamics.

By securing first-mover advantage with oral Wegovy, Novo Nordisk aims to reclaim momentum among patients reluctant to use injectables. Market forecasts project 2026 oral GLP-1 prescriptions to grow by over 40%, with Novo potentially capturing more than 60% of that segment during the initial launch period. Physician surveys indicate that efficacy and ease of administration will drive prescribing patterns, factors that favor Novo’s head start and superior trial results.

Beyond oral Wegovy, Novo Nordisk’s late-stage candidate CagriSema demonstrated a remarkable 22.7% mean weight reduction at 68 weeks in recent Phase 3 trials. If approved, this molecule could further extend the company’s lead in metabolic therapies. Analysts estimate that CagriSema could add up to $5 billion in incremental annual sales by 2028, bolstering Novo Nordisk’s long-term growth profile and supporting its strategy of continuous innovation in chronic disease management.